Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow COCP by emailGet an email when COCP pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about COCP, unsubscribe in one click. Privacy
📣 What COCP Says Is Next
late 2026 · “Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla.”
Company press release, Sep 9, 2026 · SEC filing
late 2026 · “The Company’s lead program, CDI-988, is currently in a Phase 1b clinical trial for norovirus, with topline data expected in late 2026.”
Company press release, Aug 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full COCP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COCP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.